1. As of noon trading, Gilead ( GILD) is down $0.41 (-0.5%) to $79.17 on light volume. Thus far, 4.3 million shares of Gilead exchanged hands as compared to its average daily volume of 11.7 million shares. The stock has ranged in price between $78.35-$79.93 after having opened the day at $79.40 as compared to the previous trading day's close of $79.58.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $122.9 billion and is part of the health care sector. Shares are up 6.4% year-to-date as of the close of trading on Friday. Currently there are 19 analysts that rate Gilead a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Gilead Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

If you liked this article you might like

IPOs That Should Be on Your Radar

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

Trader's Daily Notebook: Anemic Trading Would Be an Improvement